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Abstract:   
Purpose of the review: Preventing pneumonia in the elderly and subjects with 
comorbidities is an unmet clinical need. Streptococcus pneumoniae is the commonest 
bacterial cause of pneumonia, and we summarise recent findings regarding current S. 
pneumoniae vaccines, and debate their efficacy and cost effectiveness in risk groups. We 
also discuss potential future vaccine strategies such as protein antigen vaccines.  
Recent findings: Current vaccination with PPV does not prevent S. pneumoniae 
pneumonia. Vaccination with PCV prevents nasopharyngeal colonisation, but although 
PCV13 has recently been shown to prevent S. pneumoniae pneumonia in adults its overall 
efficacy was relatively low. The results of cost-effectiveness studies of PCV vaccination in 
adults are variable with some showing this is a cost effective strategy, whereas others 
have not. The lack of cost-effectiveness is predominantly due to the current cost of the 
PCV vaccine and the existing herd immunity effect from childhood PCV vaccination on 
vaccine serotypes. 
Summary: S. pneumoniae pneumonia is a vaccine preventable disease but remains a 
common cause of morbidity and mortality. Advances in vaccination using approaches that 
induce serotypes-independent immunity and are immunogenic in high risk groups are 
required to reduce the burden of disease due to S. pneumoniae.  
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Introduction 
Despite routine vaccination of children in many children with the pneumococcal 
conjugated vaccine (PCV) and adults with the pneumococcal polysaccharide vaccine 
(PPV) Streptococcus pneumoniae infection is still responsible for the greatest proportion 
of respiratory infection deaths globally amongst all age groups[1,2]. It is of particular 
concern in the elderly, with for example in the UK the incidence of pneumonia (with 40 – 
50% of cases caused by S. pneumoniae) increasing from 2.8/1000/year in 65-69 years 
age group to 22/1000/year in 85-89 years[3,4].  Even though most cases are due to strains 
that are highly susceptible to antibiotics (at least in the UK), severe S. pneumoniae 
pneumonia has a greater than 20% mortality[3,5]. Strategies to attenuate excessive 
inflammation seen in S. pneumoniae pneumonia[6,7] or enhance the immune response[8] 
may improve clinical outcomes. However, ultimately reducing the direct (via pneumonia) 
and indirect (via exacerbations of underlying lung disease) mortality caused by S. 
pneumoniae will need improved vaccines that protect against the majority of strains even 
in the elderly and in subjects with comorbidities. 
 
Existing S. pneumoniae vaccines 
The S. pneumoniae polysaccharide capsule consists of chains of repeating units of 
oligosaccharides that surround the bacterium and protect it against host-mediated 
immunity. Due to variations in their chemical structure there are over 97 serotypes of S. 
pneumoniae capsule. Current S. pneumoniae vaccines use polysaccharide capsular 
antigen either alone (PPV) or conjugated to a carrier protein (PCV). The current PPV 
(Pneumovax®23 (Merck & Co., Inc, New Jersey, USA)) consists of pneumococcal 
polysaccharide antigens covering 23 serotypes.  There are several types of PCV produced 
by different companies, and with different carrier proteins. Prevenar® (Pfizer limited, Kent, 
UK) which covers against 7 (PCV7: 4, 6B, 9V, 14, 18C, 19F and 23F) or 13 (PCV13: 1, 3, 
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4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) serotypes uses modified tetanus toxoid 
as the carrier protein, and Synflorix® GlaxoSmithKline Incp. Ontario, Canada), which 
covers against 10 (PCV10: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) serotypes uses 
Haemophilus influenzae Protein D, tetanus toxoid or diptheria toxoid as the carrier proteins 
depending on the capsular antigen. Both PPV and PCV will only induce antibody-mediated 
protection against the capsular serotypes included in the vaccine preparation.  
 
Efficacy of PPV 
Pneumovax®23 covers the 23 most frequent serotypes associated with pneumococcal 
disease. There is some suggestion that there could be some additional cross-serotype 
protection as a recent study suggest that 6B in PPV23 induced cross-functional immune 
responses against serotypes 6A and 6C[9]. In developed countries PPV is given routinely 
to adults at high-risk of S. pneumoniae infection, which includes all subjects aged 65 years 
of age and older, or those 19 – 64 years with long term health conditions, including chronic 
lung, liver, renal, cardiac and neurological disease, or who are immunocompromised. 
Although recent assessments suggest that this strategy is cost-effective[10,11], the 
effectiveness of PPV in >65 years declines significantly within 5 years of vaccination[12] 
and the introduction of routine PCV vaccination of children has reduced the cost-
effectiveness of adult vaccination with PPV due to reductions in disease caused by the 
serotypes common to both PPV and PCV. 
According to the most recent Cochrane meta-analysis PPV only prevents septicaemia 
caused by vaccine serotypes (OR 0.26, 95% CI 0.14 - 0.45)[13] and it has much weaker, 
if any, efficacy against lung infections (OR 0.72, 95% CI 0.56 - 0.93); the effect on 
pneumonia seems to be only significant in low-income countries[13]. Additionally, PPV 
trials are underpowered for detection of significant efficacy in the highest risk groups 
(chronic comorbidities or the very elderly) [13].  Hence PPV does not prevent pneumonia 
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and instead is largely used in adults to prevent septicaemia associated with S. 
pneumoniae pneumonia.  Despite this, vaccination with PPV has no overall effect on adult 
mortality (OR 0.87 95% CI 0.69-1.1), probably due to the relative low frequency of severe 
invasive S. pneumoniae infections even in the elderly compared to other causes of 
mortality. These drawbacks of PPV highlight that an alternative vaccine to the PPV will be 
necessary to reduce the burden of S. pneumoniae lung infections in adults. 
 
Efficacy of PCV in children 
As PCVs contain capsular antigen conjugated to a carrier protein they stimulate a T cell 
dependent antibody response to the capsular antigen even in infants whereas PPV does 
not, and in many developed countries all infants are routinely vaccinated with PCV. PCV 
is very effective at preventing disease in children caused by S. pneumoniae serotypes 
included in the vaccine formulations, for example causing an 80% reduction in septicaemia 
caused by vaccine serotypes[14].  The overall effect of PCV is also impressive, reducing 
the incidence of all cause (that is including cases caused by other pathogens as well as 
S. pneumoniae) radiographic proven pneumonia by 27%, and overall infant mortality in a 
developing world setting by 11%[14]. In developed countries introduction of routine 
vaccination with PCV has essentially eliminated the vaccine serotypes as causes of 
invasive S. pneumoniae infection (septicaemia and meningitis) in children. Additionally, 
vaccine failure is rare with only 2% of childhood IPD caused by PCV13 serotypes in the 
UK[15]. 
 
Herd immunity generated by PCV 
A perhaps unexpected effect of routine use of PCV in infants has been the rapid and 
dramatic reduction in nasopharyngeal colonisation with vaccine serotypes of S. 
pneumoniae. As colonisation of the nasopharynx precedes disease, prevention of 
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colonisation rather than septicaemia or lung infection is probably the main mechanism by 
which PCV prevents disease caused by S. pneumoniae.  Recent data obtained using 
mouse and a human model of experimental S. pneumoniae colonisation have 
demonstrated the mechanism by which PCV prevents colonisation. Anti-capsular antibody 
can leak into the airway lining fluid of the nasopharynx, where it agglutinates vaccine 
serotypes and this enhances their clearance from the nasopharynx before they can 
establish colonisation[16,17]. As children are the main reservoir and transmitters for S. 
pneumoniae causing disease in adults, an important consequence of eradication of 
vaccine serotypes as colonisers of infants is a significant degree of herd immunity. For 
example, routine vaccination of infants with PCV was associated with a subsequent 56% 
fall in incidence of adult pneumonia caused by vaccine serotypes[18]. However, it is 
unclear if the effect of PCV on nasopharyngeal carriage will be sustained. Results from a 
recent meta-analysis show that although protection post-PCV is sustained for some time 
the vaccine efficacy at 5 years was only 42% (95% CI 19-54%), with significant variation 
between serotypes[19]. Another recent study, although likely to be underpowered, did not 
show an association between vaccination status and serotype carriage in children with 
asthma[20]. Additionally, approximately 20% of all IPD cases are still caused by PCV13 
serotypes[18] and the herd effect alone is not sufficient to completely protect adults from 
non-bacteraemic pneumococcal pneumonia caused by vaccine serotypes [21]. An 
important consequence observed in multiple countries of the large reductions in the 
nasopharyngeal carriage of S. pneumoniae vaccine serotypes in response to PCV is a 
compensatory major expansion in the prevalence of non-vaccine serotypes as 
nasopharyngeal commensals, and inevitably as a cause of disease[18,22–24]. The 
expansion of disease caused by non-vaccine serotypes particularly affects herd immunity 
benefits for adults[18]. 
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Adult vaccination with PCV 
Given the efficacy of PCV at preventing pneumonia in children, an obvious strategy to 
overcome the limitations of PPV vaccination at preventing lung infection is to vaccinate 
adults with PCV. The efficacy of PCV at preventing pneumonia and IPD in adults was 
assessed by the CAPITA study. In this 5 year study 84,496 adults aged 65 years or over 
were either vaccinated with PCV13 or placebo[25]. The mean age of the subjects was 73 
years, 55% were male, and 42% had at least one comorbidity. PCV had an efficacy of 
46% (95% CI 22-63%) and 75% (95% CI 41-91%) at preventing pneumonia and IPD due 
to vaccine serotypes, respectively. However, only 36% of S. pneumoniae pneumonia 
cases were due to vaccine serotypes, hence the overall efficacy of PCV protecting against 
S. pneumoniae pneumonia was 31% (95% CI 10-47%). Efficacy against all cause 
pneumonia was only 5% (95% CI -5.1-4.2%)[25] and since the microbiological diagnosis 
is not made for many cases of pneumonia[26] the vaccine efficacy in protecting against S. 
pneumoniae pneumonia may be overestimated. Additionally, there was no effect on 
overall mortality[25]. Hence, the absolute effect of PCV13 was relatively weak. Importantly, 
the CAPITA study highlights that only extremely large clinical trials will be able to 
demonstrate the efficacy of preventative measures against pneumonia and death.  
There are only limited additional data on PCV efficacy in adults to the CAPITA study. An 
Italian observational cohort of adults > 65 years hospitalised with CAP suggested those 
who had received PCV had increased survival compared to vaccination with PPV[27]. In 
the elderly antibody responses to PPV are impaired[28] and vaccine efficacy is reduced 
with time[12].  A prime boost approach of administration of one dose PCV13 to aged 
individuals previously given PPV23 may overcome this, as this strategy induces higher 
opsonophagocytosis titres for 11 of 13 serotypes [29]. A second dose of PCV13 did not 
result in any additional benefit.  
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Vaccination with PCV is expensive, and PCV efficacy in adults will be undermined by the 
reduction in prevalence of vaccine serotypes due to PCV vaccination of infants. Therefore, 
national bodies considering introducing PCV into routine use in adults need to carefully 
consider the cost effectiveness of this vaccine strategy. However, cost effectiveness 
assessments have given variable results. Dutch and Japanese studies suggested that 
using PCV in adults >65 years would be cost effective[30,31], yet the UK Joint Committee 
on Vaccination and Immunisation came to the opposite conclusion and suggest PCV 
should only be given to adults who are immunocompromised[32]. Other more recent 
assessments have also concluded that PCV in adults would not be cost-effective when 
taking into account the anticipated herd protection seen with infant immunisation[33–35]. 
However, in adults with co-morbidities such as COPD PCV13 maybe more likely to be 
cost-effective than PPV23 [36,37]. 
Two potential considerations could improve the cost effectiveness of PCV in adults. Firstly 
if PCV could prevent the 25% of infective exacerbations of COPD (one of the commonest 
causes for emergency admission to hospital) that are associated with S. pneumoniae that 
would markedly improve the cost effectiveness of using PCV in adults. However the 
anatomical and immunological effects of chronic lung disease could readily impair PCV 
protective efficacy; furthermore non-serotypable strains are a significant cause of 
infections in patients with COPD [38]. Further data are needed on the efficacy of PCV 
against infective exacerbations of COPD. Secondly, the PCV preparation used in the 
CAPITA study was designed for preventing serotypes associated with invasive disease in 
children; an adult specific PCV formulated to include serotypes that cause lung infection 
in populations in which children are already routinely vaccinated with PCV could be more 
cost effectiveness. However, altering PCV serotype coverage is at present a prohibitively 
expensive process. 
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Future directions 
Natural adaptive immunity to S. pneumoniae: As discussed above existing vaccines are 
unlikely to be adequate at preventing adult S. pneumoniae lung infections, and there 
remains a strong need for alternative cost-effective approaches that are not limited to 
preventing infection by only a small subset of S. pneumoniae serotypes. Repetitive 
colonisation of the human nasopharynx with S. pneumoniae is ubiquitous in children and 
is now known to stimulate a strong protective adaptive immune response, and this is 
thought to contribute to the large fall in pneumococcal carriage rate at the end of infancy. 
A combination of longitudinal studies of natural human colonisation and mouse and human 
models have shown that colonisation induces both humoral and cellular immune 
responses to multiple protein antigens as well as antibody against capsular 
polysaccharide[39,40]. In mouse models lung immunity to S. pneumoniae seems to 
require both an antibody and a CD4 Th17 response to protein antigens[39]. As the protein 
antigen targets are often highly conserved between S. pneumoniae strains, these data 
provide a potential starting point for novel vaccines that provide universal protection 
against all S. pneumoniae strains and can protect against lung infection.   
 
Effect of immunosenescence on adaptive immunity to S. pneumoniae: The high incidence 
of S. pneumoniae infections in the elderly is at least partly due to waning of naturally-
acquired adaptive immune responses due to immunosenescence – the changes in 
immune function associated with natural ageing. Ageing is associated with several defects 
in immune responses and metabolic activity that can result in impaired innate and adaptive 
immunity, as well as vaccine immunogenicity. These are not only associated with loss of 
immune function; some aspects of the aged immune system can also be preserved while 
others are in fact enhanced, such as the chronic low level inflammation seen in the elderly 
(known as “inflammaging”).  The interactions between these different effects of age on 
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immune responses are complex and their downstream consequences on host 
susceptibility to S. pneumoniae or response to vaccination are poorly understood. Likely 
to be important are the decrease in number and function of antigen presentation cells, loss 
of naïve B- and T-cells with a corresponding increase in memory cells, with responses 
becoming more homogenous and less antigen specific with increasing age[41,42]. Aged 
T-cells also have a less diverse repertoire which reduces the ability to mount responses 
to novel antigens[42]. Importantly, the elderly have reduced frequency of Th17 memory T-
cells[41], which might be particularly relevant for the development of pneumonia. A 
detailed analysis of the natural adaptive immune responses that protect adults against S. 
pneumoniae lung infection and how they are affected by age may identify novel strategies 
for preventing adult S. pneumoniae pneumonia. For example, the immunogenicity of 
vaccines in the elderly could be optimised by either simple measures such as increasing 
antigen dose or altering dose scheduling, or by more complex strategies designed to 
overcome specific aspects of immunosenescence using novel adjuvants, 
immunomodulators to reverse the effects of inflammaging, or developing vector based 
vaccines that target CD8 T-cell responses that are preserved in the elderly[42–44]. 
 
Novel vaccine approaches: S. pneumoniae protein antigens are conserved amongst a 
large majority of strains and vaccine approaches using these antigens may therefore offer 
cross-serotype protection. Several protein antigens have been shown to be highly 
immunogenic and can elicit antibody or Th17 CD4 responses[45] that protect against 
colonisation or infection in murine models (Error! Reference source not found.). The 
vaccine antigens PhtD, StkP, PcsB and PsaA have been used in phase I/II clinical trials 
and although they all demonstrate immunogenicity and are considered safe as yet no 
protein vaccine has progressed to a phase III trial[45].  Other novel approaches include 
the identification and development of a semi-synthetic oligosaccharide conjugate vaccine 
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(tetrasaccharide-CRM197 carrier protein conjugate), the use of whole-cell killed 
pneumococci, and novel heat shock protein multivalent S. pneumoniae protein antigen 
vaccines that are protective against murine pneumonia[46–49]. 
 
Conclusion 
Current S. pneumoniae vaccination strategies are only partially effective at preventing 
pneumonia in the elderly, and good quality studies investigation the effects of vaccination 
on clinical outcomes in this age group are lacking. Novel approaches vaccines such as 
protein antigen, killed whole bacteria, or vector based vaccines need to be identified to 
cover the majority of S. pneumoniae serotypes and improve vaccine efficacy in high-risk 
groups. Furthermore, the development of novel strategies to counter the effects of 
immunosenescence on natural and vaccine acquired immunity may also improve 
prevention of S. pneumoniae pneumonia in risk groups. Novel models such as the 
experimental human pneumococcal colonisation model[50] may be the ideal biological 
system in which to the study the effects of vaccines or immunomodulators on mucosal 
immunity to S. pneumoniae in humans whilst avoiding the expense of a large clinical trial 
of  efficacy against disease.  
 
Key points: 
1. Current S. pneumoniae vaccination strategies are only partially effective at preventing 
adult S. pneumoniae pneumonia.  
2. Novel vaccine approaches will be required to prevent the high morbidity and mortality 
caused by S. pneumoniae pneumonia in the elderly and subjects with chronic lung 
disease  
3. An understanding of the effects of age on immunity to S. pneumoniae will be 
important for the development of effective novel preventative strategies. 
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9 * Interesting study that demonstrates that the polysaccharide of one serotype 
present in the pneumococcal vaccine can potentially protect adults from serotypes 
in the same serogroup 
 
16 * Important study which highlights the importance of agglutination antibodies 
for mucosal host defence 
 
17 ** Important study that demonstrates how agglutination antibodies to 
pneumococcal polysaccharide capsule limits nasopharyngeal carriage in a novel 
experimental human pneumococcal carriage model 
 
18 ** Important epidemiological study looking at the effect of 8 years of PCV use in 
England and Wales 
 
22 * Important study highlighting the emergence of macrolide resistance genes in 
non-PCV serotypes.  
 
25 ** Outstanding study demonstrating the efficacy of PCV13 in reducing vaccine 
serotype pneumonia and IPD in adults 
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35 * Important study which demonstrates that PCV in adults is efficacious but will 
not be cost-effective in the immunocompetent elderly due to the benefits seen with 
PCV13 immunisation in children.   
  
41 * Extensive review of the potential effects of age on innate immunity to S. 
pneumoniae 
 
50 ** Important study demonstrating the usefulness of the experimental human 
pneumococcal carriage model to investigate the effects of novel vaccines on S. 
pneumoniae nasal colonisation.  
